Northern Trust Corp Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN

Northern Trust Corp raised its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 1.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 702,517 shares of the company’s stock after acquiring an additional 8,375 shares during the quarter. Northern Trust Corp’s holdings in Viridian Therapeutics were worth $9,470,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of VRDN. Amalgamated Bank boosted its stake in Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after acquiring an additional 840 shares in the last quarter. GAMMA Investing LLC boosted its stake in Viridian Therapeutics by 3,892.9% during the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after acquiring an additional 8,214 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Viridian Therapeutics during the fourth quarter worth about $258,000. ProShare Advisors LLC boosted its stake in Viridian Therapeutics by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 20,584 shares of the company’s stock worth $395,000 after acquiring an additional 8,761 shares in the last quarter. Finally, Knott David M Jr boosted its stake in Viridian Therapeutics by 20.0% during the first quarter. Knott David M Jr now owns 30,000 shares of the company’s stock worth $404,000 after acquiring an additional 5,000 shares in the last quarter.

Viridian Therapeutics Stock Up 0.4%

Shares of VRDN stock opened at $18.72 on Friday. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The stock has a market cap of $1.53 billion, a P/E ratio of -4.89 and a beta of 0.53. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The company has a 50 day simple moving average of $17.37 and a two-hundred day simple moving average of $15.23.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, meeting analysts’ consensus estimates of ($1.00). The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.81) earnings per share. On average, research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VRDN shares. Jefferies Financial Group started coverage on shares of Viridian Therapeutics in a research note on Monday, August 25th. They issued a “buy” rating and a $44.00 target price on the stock. Wells Fargo & Company dropped their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. Needham & Company LLC dropped their target price on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Oppenheimer upped their target price on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. Finally, Royal Bank Of Canada dropped their target price on shares of Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.78.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.